O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes

Abstract Background Sodium oxybate (SOX) is an evidenced based treatment for narcolepsy. SOX is not available in Australia through the pharmaceutical benefits scheme. In 2018, Western Australia (WA) listed sodium oxybate on the state formulary for the treatment of refractory narcolepsy. We examine the demographics, clinical and employment outcomes of patients treated with SOX. Methods We undertook a retrospective study of patients treated with sodium oxybate in WA for refractory narcolepsy or idiopathic hypersomnia (IH). A database of SOX patients was cross checked with pharmacy prescribing data from across WA public hospitals. Electronic medical records were used to collect demographic, polysomnographic, prescribing and outcome data. Clinical outcomes were based on the Epworth sleepiness scale, clinical assessment and employment status. Patients that responded to SOX are to be compared to non-responders using appropriate statistical methodology. Progress to date The study has been registered as a hospital clinical audit (number 49852). A total of 50 patients prescribed SOX for the treatment of a central hypersomnia have been identified. A request for sodium oxybate dispensing data across WA has been made. Review of 10 patient’s records has been completed. Correspondence, sleep studies, MSLT, HLA testing and prescriptions are being reviewed for the remaining 40 patients. Intended outcome and impact Describe the characteristics of patients treated with SOX in WA. Explore whether clinical or sleep study characteristics predict response to SOX. Assess patient reported outcomes from treatment with SOX based on symptoms and changes in employment status.